Certified Clinical Trials Pharmacist (CCTP®) Exam Prep
2026 Updated Practice Questions — Comprehensive Clinical
Trial Professional Review Detailed Explanations, Verified
Answers, Complete Success Workbook
DOMAIN 1: Regulatory Compliance & Protocol Management (20%)
Question 1
The Investigational Drug Service (IDS) pharmacist receives a protocol for a new
multi-center oncology trial. According to Good Clinical Practice (GCP), what is
one of the MOST critical initial responsibilities of the pharmacist?
A) Ordering all investigational product immediately
B) Developing a comprehensive, study-specific procedure manual for drug
preparation, dispensing, and accountability
C) Contacting all potential study subjects
D) Submitting the protocol to the FDA
Rationale: Developing a comprehensive, study-specific procedure manual is a
core function of an IDS pharmacist to ensure the protocol is followed precisely,
safely, and consistently. This manual serves as the operational foundation for all
pharmacy-related trial activities and ensures consistency across staff members.
Question 2
Which federal regulation governs Investigational New Drug (IND) applications in
the United States?
A) 21 CFR Part 50
B) 21 CFR Part 312
C) 21 CFR Part 56
D) 45 CFR Part 46
Rationale: 21 CFR Part 312 governs Investigational New Drug (IND)
applications. 21 CFR Part 50 governs informed consent, Part 56 governs IRB
requirements, and 45 CFR Part 46 is the Common Rule for human subject
protection.
,Question 3
A clinical trial pharmacist is reviewing a protocol for pharmacy feasibility. Which
of the following should be evaluated FIRST?
A) The number of study sites
B) The medication-related sections of the protocol to identify operational
challenges and resource requirements
C) The statistical analysis plan
D) The publication plan
Rationale: The pharmacist should analyze medication-related sections of a
protocol to identify and mitigate operational challenges. This includes
evaluating IP preparation, administration, monitoring requirements, and resource
needs (staffing, equipment, space) before committing to study participation.
Question 4
According to ICH GCP, what is the primary purpose of Good Clinical Practice?
A) To reduce the cost of clinical research
B) To provide assurance that the data and reported results are credible and
accurate and that the rights, safety, and well-being of trial subjects are
protected
C) To accelerate drug approval timelines
D) To maximize sponsor profitability
Rationale: ICH GCP provides an international ethical and scientific quality
standard for designing, conducting, recording, and reporting trials involving human
subjects. Its primary purpose is to provide assurance that data and reported
results are credible and accurate, and that the rights, safety, and well-being of
trial subjects are protected.
Question 5
Which document must be submitted to the IRB for review when a pharmacist
identifies a need to modify pharmacy procedures related to a clinical trial?
,A) IND application
B) Protocol amendment
C) Investigator's Brochure
D) Annual report
Rationale: Any change to pharmacy procedures that affects the conduct of the trial
requires a protocol amendment. The pharmacist must reconcile protocol
amendments with pharmacy operational procedures and documentation, and all
amendments must be submitted to the IRB for review and approval before
implementation.
Question 6
What is the pharmacist's responsibility regarding the informed consent form (ICF)
in a clinical trial?
A) To obtain informed consent from all subjects
B) To validate that the ICF accurately describes medication procedures, risks,
and responsibilities
C) To sign the ICF on behalf of the subject
D) To file the ICF with the FDA
Rationale: The pharmacist must validate that the informed consent form (ICF)
accurately describes medication procedures, risks, and responsibilities. This
ensures that subjects fully understand the medication-related aspects of the trial
before consenting to participate.
Question 7
Under 21 CFR Part 312, what is the timeframe for submitting an IND Safety
Report to the FDA for a fatal or life-threatening unexpected suspected adverse
reaction?
A) 24 hours
B) 7 calendar days
C) 15 calendar days
D) 30 calendar days
Rationale: Under 21 CFR 312.32, IND Safety Reports for fatal or life-
threatening unexpected suspected adverse reactions must be submitted to the
, FDA within 7 calendar days. Other serious unexpected suspected adverse
reactions must be submitted within 15 calendar days.
Question 8
Which of the following is a key regulatory responsibility of the sponsor regarding
investigational product?
A) Dispensing IP directly to subjects
B) Providing the investigator with the Investigator's Brochure and ensuring
proper IP labeling
C) Administering IP to subjects
D) Obtaining informed consent
Rationale: The sponsor is responsible for providing the investigator with the
Investigator's Brochure and ensuring proper IP labeling. The sponsor must
also ensure that the IP is manufactured, packaged, and labeled in accordance with
GCP and regulatory requirements.
Question 9
A pharmacist is preparing pharmacy documents for an initial IRB submission.
Which of the following is typically required?
A) Only the protocol
B) The protocol, pharmacy manual, informed consent form (pharmacy
sections), and drug information sheets
C) Only the Investigator's Brochure
D) Only the FDA Form 1572
Rationale: The pharmacist must prepare and manage all pharmacy-related
documents for IRB submissions. This includes the protocol, pharmacy manual,
ICF pharmacy sections, drug information sheets, and any other documents relevant
to medication management in the trial.
Question 10
What is the primary purpose of the Investigator's Brochure (IB) for a clinical trial
pharmacist?
2026 Updated Practice Questions — Comprehensive Clinical
Trial Professional Review Detailed Explanations, Verified
Answers, Complete Success Workbook
DOMAIN 1: Regulatory Compliance & Protocol Management (20%)
Question 1
The Investigational Drug Service (IDS) pharmacist receives a protocol for a new
multi-center oncology trial. According to Good Clinical Practice (GCP), what is
one of the MOST critical initial responsibilities of the pharmacist?
A) Ordering all investigational product immediately
B) Developing a comprehensive, study-specific procedure manual for drug
preparation, dispensing, and accountability
C) Contacting all potential study subjects
D) Submitting the protocol to the FDA
Rationale: Developing a comprehensive, study-specific procedure manual is a
core function of an IDS pharmacist to ensure the protocol is followed precisely,
safely, and consistently. This manual serves as the operational foundation for all
pharmacy-related trial activities and ensures consistency across staff members.
Question 2
Which federal regulation governs Investigational New Drug (IND) applications in
the United States?
A) 21 CFR Part 50
B) 21 CFR Part 312
C) 21 CFR Part 56
D) 45 CFR Part 46
Rationale: 21 CFR Part 312 governs Investigational New Drug (IND)
applications. 21 CFR Part 50 governs informed consent, Part 56 governs IRB
requirements, and 45 CFR Part 46 is the Common Rule for human subject
protection.
,Question 3
A clinical trial pharmacist is reviewing a protocol for pharmacy feasibility. Which
of the following should be evaluated FIRST?
A) The number of study sites
B) The medication-related sections of the protocol to identify operational
challenges and resource requirements
C) The statistical analysis plan
D) The publication plan
Rationale: The pharmacist should analyze medication-related sections of a
protocol to identify and mitigate operational challenges. This includes
evaluating IP preparation, administration, monitoring requirements, and resource
needs (staffing, equipment, space) before committing to study participation.
Question 4
According to ICH GCP, what is the primary purpose of Good Clinical Practice?
A) To reduce the cost of clinical research
B) To provide assurance that the data and reported results are credible and
accurate and that the rights, safety, and well-being of trial subjects are
protected
C) To accelerate drug approval timelines
D) To maximize sponsor profitability
Rationale: ICH GCP provides an international ethical and scientific quality
standard for designing, conducting, recording, and reporting trials involving human
subjects. Its primary purpose is to provide assurance that data and reported
results are credible and accurate, and that the rights, safety, and well-being of
trial subjects are protected.
Question 5
Which document must be submitted to the IRB for review when a pharmacist
identifies a need to modify pharmacy procedures related to a clinical trial?
,A) IND application
B) Protocol amendment
C) Investigator's Brochure
D) Annual report
Rationale: Any change to pharmacy procedures that affects the conduct of the trial
requires a protocol amendment. The pharmacist must reconcile protocol
amendments with pharmacy operational procedures and documentation, and all
amendments must be submitted to the IRB for review and approval before
implementation.
Question 6
What is the pharmacist's responsibility regarding the informed consent form (ICF)
in a clinical trial?
A) To obtain informed consent from all subjects
B) To validate that the ICF accurately describes medication procedures, risks,
and responsibilities
C) To sign the ICF on behalf of the subject
D) To file the ICF with the FDA
Rationale: The pharmacist must validate that the informed consent form (ICF)
accurately describes medication procedures, risks, and responsibilities. This
ensures that subjects fully understand the medication-related aspects of the trial
before consenting to participate.
Question 7
Under 21 CFR Part 312, what is the timeframe for submitting an IND Safety
Report to the FDA for a fatal or life-threatening unexpected suspected adverse
reaction?
A) 24 hours
B) 7 calendar days
C) 15 calendar days
D) 30 calendar days
Rationale: Under 21 CFR 312.32, IND Safety Reports for fatal or life-
threatening unexpected suspected adverse reactions must be submitted to the
, FDA within 7 calendar days. Other serious unexpected suspected adverse
reactions must be submitted within 15 calendar days.
Question 8
Which of the following is a key regulatory responsibility of the sponsor regarding
investigational product?
A) Dispensing IP directly to subjects
B) Providing the investigator with the Investigator's Brochure and ensuring
proper IP labeling
C) Administering IP to subjects
D) Obtaining informed consent
Rationale: The sponsor is responsible for providing the investigator with the
Investigator's Brochure and ensuring proper IP labeling. The sponsor must
also ensure that the IP is manufactured, packaged, and labeled in accordance with
GCP and regulatory requirements.
Question 9
A pharmacist is preparing pharmacy documents for an initial IRB submission.
Which of the following is typically required?
A) Only the protocol
B) The protocol, pharmacy manual, informed consent form (pharmacy
sections), and drug information sheets
C) Only the Investigator's Brochure
D) Only the FDA Form 1572
Rationale: The pharmacist must prepare and manage all pharmacy-related
documents for IRB submissions. This includes the protocol, pharmacy manual,
ICF pharmacy sections, drug information sheets, and any other documents relevant
to medication management in the trial.
Question 10
What is the primary purpose of the Investigator's Brochure (IB) for a clinical trial
pharmacist?
